Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE4
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Nivolumab in Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab in AML in Remission at High Risk for Relapse
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab With DC Vaccines for Recurrent Brain Tumors
- Status
- COMPLETED
- Phase
- PHASE1